SG11201401517VA - Etanercept formulations stabilized with combinations of sugars and polyols - Google Patents

Etanercept formulations stabilized with combinations of sugars and polyols

Info

Publication number
SG11201401517VA
SG11201401517VA SG11201401517VA SG11201401517VA SG11201401517VA SG 11201401517V A SG11201401517V A SG 11201401517VA SG 11201401517V A SG11201401517V A SG 11201401517VA SG 11201401517V A SG11201401517V A SG 11201401517VA SG 11201401517V A SG11201401517V A SG 11201401517VA
Authority
SG
Singapore
Prior art keywords
polyols
sugars
combinations
etanercept formulations
formulations stabilized
Prior art date
Application number
SG11201401517VA
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161548518P priority Critical
Priority to US201261669480P priority
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Priority to PCT/US2012/060748 priority patent/WO2013059412A1/en
Publication of SG11201401517VA publication Critical patent/SG11201401517VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11201401517VA 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols SG11201401517VA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161548518P true 2011-10-18 2011-10-18
US201261669480P true 2012-07-09 2012-07-09
PCT/US2012/060748 WO2013059412A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Publications (1)

Publication Number Publication Date
SG11201401517VA true SG11201401517VA (en) 2014-09-26

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Country Status (17)

Country Link
US (11) US9801942B2 (en)
EP (6) EP2768531A4 (en)
JP (6) JP6199298B2 (en)
KR (6) KR20140079491A (en)
CN (6) CN103998060B (en)
AR (6) AR088382A1 (en)
AU (6) AU2012326080B2 (en)
BR (6) BR112014009022A2 (en)
CA (6) CA2851642A1 (en)
EA (6) EA028520B1 (en)
HK (6) HK1200718A1 (en)
IL (6) IL231828D0 (en)
IN (3) IN2014CN02527A (en)
MX (6) MX2014004725A (en)
SG (6) SG11201401517VA (en)
TW (6) TWI595883B (en)
WO (6) WO2013059412A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004725A (en) * 2011-10-18 2015-02-05 Coherus Biosciences Inc Etanercept formulations stabilized with amino acids.
JP6271536B2 (en) * 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド Etanercept formulations that exhibit a significant reduction in macroscopic visible particles
DK2895188T3 (en) * 2012-09-11 2018-02-26 Coherus Biosciences Inc Properly folded etanercept in high purity and excellent yield
MX2015015051A (en) * 2013-05-02 2016-06-10 Mabxience S A Alternative formulations for tnfr: fc fusion polypeptides.
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Meiji Seikaファルマ株式会社 Stabilized polypeptide aqueous preparation
CN105611938A (en) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 Stable, aqueous antibody formulations
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (en) * 2014-05-14 2018-12-15 Calor ehf A peptide or protein stabilizing formulation
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
BR112017013269A2 (en) * 2014-12-22 2018-02-27 Ares Trading Sa ? Liquid pharmaceutical composition?
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
JP2018503630A (en) * 2014-12-31 2018-02-08 エルジー・ケム・リミテッド Method for producing a TNFR-Fc fusion protein containing impurities in a content of interest
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Pueraria liver health wine and its preparation method
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
JP5938762B1 (en) * 2015-09-01 2016-06-22 日揮株式会社 Microcapsule formulations and manufacturing method thereof
CN105748414A (en) * 2016-03-02 2016-07-13 张光泉 Anti-infection micafungin freeze-drying composition and preparation method thereof
JPWO2017179683A1 (en) * 2016-04-15 2019-02-21 Meiji Seikaファルマ株式会社 Stabilized pharmaceutical composition of micafungin
WO2019087108A1 (en) * 2017-10-31 2019-05-09 Probiomed S.A. De C.V. Stable pharmaceutical formulation of a fusion protein

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
EP0852951A1 (en) 1996-11-19 1998-07-15 Boehringer Mannheim Gmbh Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CN1406132A (en) 2000-02-10 2003-03-26 惠氏公司 Method for treating or inhibiting cellular injury or cell death
AU2003219958B2 (en) 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
DE602004013557D1 (en) 2003-02-28 2008-06-19 Ares Trading Sa LIQUID FORMULATIONS OF TUMORNEKROSEFRAKTOR binding protein TBP-1
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
AU2004262014B2 (en) * 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
EA011857B8 (en) 2003-10-14 2012-08-30 Интермьюн, Инк. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005082377A1 (en) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITOR FOR LOWERING IN THE ACTIVITY OF ANTIHUMAN TNF-α ANTIBODY
ES2456015T3 (en) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Method for culturing cells by continuous infusion and alternating tangential flow
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
PT1962886E (en) 2005-12-20 2014-01-07 Squibb Bristol Myers Co Stable protein formulations
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
BRPI0709598A8 (en) 2006-03-17 2019-01-08 Biogen Idec Inc stabilized polypeptide compositions
CA2649538C (en) 2006-04-21 2014-06-03 Yatin Gokarn Buffering agents for biopharmaceutical formulations
CL2007002880A1 (en) 2006-10-06 2008-05-09 Amgen Inc Stable formulation comprising an acetic acid buffer, glutamic acid buffer or succinic acid buffer with a pH of 4.5 to 7, at least one excipient comprising a sugar or a polyol, and an anti-receptor factor d
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
WO2008055260A2 (en) 2006-11-03 2008-05-08 Wyeth Glycolysis-inhibiting substances in cell culture
AU2007338791B2 (en) * 2006-12-21 2014-03-13 Amgen Inc Stable buffered formulations containing polypeptides
JP5586235B2 (en) 2007-03-02 2014-09-10 ワイス・エルエルシー Use of copper and glutamate in cell culture for the production of a polypeptide
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
SI2170390T1 (en) * 2007-06-14 2019-02-28 Biogen Ma Inc. Natalizumab antibody formulations
TWI629064B (en) * 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 Protein formulations and manufacturing method therefor
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
EP2260054B1 (en) 2008-02-29 2015-06-03 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SG10201500822XA (en) 2009-08-11 2015-04-29 Genentech Inc Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
ES2684921T3 (en) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited liquid formulation containing an Fc polypeptide domain of an immunoglobulin
WO2012013980A1 (en) * 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Etanercept stable liquid formulation
CA2840711A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
EA201391826A1 (en) 2011-07-01 2014-04-30 Амген Инк. Cultivation of mammalian cells
MX2014004725A (en) * 2011-10-18 2015-02-05 Coherus Biosciences Inc Etanercept formulations stabilized with amino acids.

Also Published As

Publication number Publication date
US20130101640A1 (en) 2013-04-25
IN2014CN02527A (en) 2015-06-26
AU2012326168A1 (en) 2014-04-24
KR20140091705A (en) 2014-07-22
JP2014530864A (en) 2014-11-20
AR088381A1 (en) 2014-05-28
EA201490804A1 (en) 2014-09-30
KR20140091706A (en) 2014-07-22
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
WO2013059408A1 (en) 2013-04-25
EP2768535A4 (en) 2015-03-11
JP2014530863A (en) 2014-11-20
TW201325607A (en) 2013-07-01
AU2012326168B2 (en) 2016-12-15
TWI595883B (en) 2017-08-21
US9302002B2 (en) 2016-04-05
US20160317667A1 (en) 2016-11-03
EP2768533A4 (en) 2015-03-11
BR112014009073A2 (en) 2017-05-09
EP2768532A4 (en) 2015-03-11
AR088382A1 (en) 2014-05-28
EA201490803A1 (en) 2014-09-30
US20160199489A1 (en) 2016-07-14
SG11201401563SA (en) 2014-09-26
CN104010658A (en) 2014-08-27
AR088383A1 (en) 2014-05-28
EP2768533A1 (en) 2014-08-27
AU2012326084A1 (en) 2014-04-17
EA027325B1 (en) 2017-07-31
SG11201401567YA (en) 2014-07-30
EP2768531A1 (en) 2014-08-27
US9943601B2 (en) 2018-04-17
IL231828D0 (en) 2014-05-28
EP2768531A4 (en) 2015-03-11
KR20140079491A (en) 2014-06-26
CN103998061A (en) 2014-08-20
JP6220788B2 (en) 2017-10-25
JP6220789B2 (en) 2017-10-25
SG11201401562RA (en) 2014-09-26
SG11201401519RA (en) 2014-07-30
CA2851628A1 (en) 2013-04-25
SG11201401576WA (en) 2014-10-30
EA201490801A1 (en) 2014-09-30
CA2851639A1 (en) 2013-04-25
AU2012326171A1 (en) 2014-04-24
WO2013059407A1 (en) 2013-04-25
AU2012326082A1 (en) 2014-04-24
MX2014004734A (en) 2015-05-15
US9801942B2 (en) 2017-10-31
US20190216930A1 (en) 2019-07-18
JP6104922B2 (en) 2017-03-29
IN2014CN02592A (en) 2015-09-04
US10213508B2 (en) 2019-02-26
TWI619504B (en) 2018-04-01
EA201490802A1 (en) 2014-08-29
IL231829D0 (en) 2014-05-28
IL231825D0 (en) 2014-05-28
HK1200851A1 (en) 2015-08-14
KR20140091707A (en) 2014-07-22
EA026410B1 (en) 2017-04-28
BR112014009146A8 (en) 2017-06-20
US20130108632A1 (en) 2013-05-02
BR112014009131A8 (en) 2017-06-20
WO2013059406A1 (en) 2013-04-25
EP2768854A4 (en) 2015-03-11
EP2768525A4 (en) 2015-07-15
BR112014009146A2 (en) 2017-06-13
WO2013059412A1 (en) 2013-04-25
AR088379A1 (en) 2014-05-28
HK1200721A1 (en) 2015-08-14
AR088380A1 (en) 2014-05-28
BR112014009087A2 (en) 2017-04-18
US20190184017A1 (en) 2019-06-20
US20180125982A1 (en) 2018-05-10
AU2012326080B2 (en) 2017-02-16
IL231826D0 (en) 2014-05-28
EP2768854A1 (en) 2014-08-27
US20130101584A1 (en) 2013-04-25
CN104011073B (en) 2017-08-25
TW201325606A (en) 2013-07-01
BR112014009131A2 (en) 2017-06-13
CN104011073A (en) 2014-08-27
EA028520B1 (en) 2017-11-30
EA025267B1 (en) 2016-12-30
AU2012326170B2 (en) 2016-12-22
AU2012326171B2 (en) 2017-03-09
AU2012326082B2 (en) 2016-12-15
CA2851646A1 (en) 2013-04-25
HK1200718A1 (en) 2015-08-14
HK1200722A1 (en) 2015-08-14
CA2851635A1 (en) 2013-04-25
TWI644681B (en) 2018-12-21
AR088460A1 (en) 2014-06-11
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
CN104010654B (en) 2017-10-27
AU2012326080A1 (en) 2014-04-24
EA025663B1 (en) 2017-01-30
JP6113176B2 (en) 2017-04-12
AU2012326170A1 (en) 2014-04-24
JP2014530254A (en) 2014-11-17
WO2013059405A1 (en) 2013-04-25
BR112014009022A2 (en) 2017-05-02
BR112014009031A2 (en) 2017-05-09
EP2768525B1 (en) 2019-06-19
TW201325608A (en) 2013-07-01
EA201490817A1 (en) 2014-09-30
EP2768535A1 (en) 2014-08-27
IL231824D0 (en) 2014-05-28
IL231827D0 (en) 2014-05-28
CA2851642A1 (en) 2013-04-25
US9770510B2 (en) 2017-09-26
TW201325610A (en) 2013-07-01
EP2768525A1 (en) 2014-08-27
JP2014530255A (en) 2014-11-17
MX2014004726A (en) 2015-05-15
CN103998060A (en) 2014-08-20
EA201490815A1 (en) 2014-09-30
HK1200720A1 (en) 2015-08-14
TW201325609A (en) 2013-07-01
US20180193463A1 (en) 2018-07-12
CA2851651A1 (en) 2013-04-25
JP2014530256A (en) 2014-11-17
AU2012326084B2 (en) 2016-12-15
TW201325611A (en) 2013-07-01
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (en) 2015-06-26
EP2768532A1 (en) 2014-08-27
CN104010654A (en) 2014-08-27
JP2014530862A (en) 2014-11-20
JP6110393B2 (en) 2017-04-05
CN104010657A (en) 2014-08-27
JP6199298B2 (en) 2017-09-20
KR20140097184A (en) 2014-08-06
MX2014004732A (en) 2015-05-15
US20130108633A1 (en) 2013-05-02
MX2014004728A (en) 2015-05-15
KR20140083037A (en) 2014-07-03
MX2014004725A (en) 2015-02-05
CN103998060B (en) 2016-12-21
MX2014004733A (en) 2015-05-15

Similar Documents

Publication Publication Date Title
TWI538852B (en) Personal aircraft
GB2516540B (en) Protective case and methods of making
TWI625127B (en) Pharmaceutical compositions comprising human antibodies to pcsk9
TWI586687B (en) Antibodies to pcsk9 and uses thereof
TWI586366B (en) Stabilized formulations containing anti-pcsk9 antibodies
TWI585062B (en) Synthetic formulations and methods of manufacturing and using thereof
TWM421896U (en) Improved structure of chair
ZA201400678B (en) Alpha-amylase variants
PL2734522T3 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2763541A4 (en) Pest control formulations and methods of making and using same
HK1188194A1 (en) Beverage delivery pod and methods of use and manufacture
PL2591114T3 (en) Immunisation of large mammals with low doses of rna
EP2721019A4 (en) Therapeutically active compositions and their methods of use
EP2694095A4 (en) Compositions comprising glucagon analogs and methods of making and using the same
EP2635690A4 (en) Compositions and methods for production of fermentable sugars
EP2661264A4 (en) Melanin modification compositions and methods of use
TWI616138B (en) Pesticidal compositions and methods of using the same
EP2667915A4 (en) Injector
HK1202071A1 (en) Biocidal compositions and methods of using the same
IL228721A (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines and pharmaceutical compositions thereof
EP2670434A4 (en) Treatment of tauopathies
HK1193837A1 (en) Polyurea compositions and methods of use
TWI453516B (en) Pixel structure and method of making the same
EP2768525A4 (en) Etanercept formulations stabilized with metal ions
IL229431D0 (en) Anti-cgrp composition and use thereof